Rare diseases
Investigational molecules
Locations
Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
AustriaDurvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer
ItalySacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
AustriaStudy of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma
FranceStudy on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma
GermanyStudy of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
AustriaStudy on Sonoporation-Enhanced Treatment with Gemcitabine, Nab-Paclitaxel, and FOLFIRINOX for Patients with Inoperable Pancreatic Cancer
NorwayStudy on the Safety and Effectiveness of Mitazalimab with Chemotherapy for Patients with Metastatic Pancreatic Cancer
BelgiumStudy on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy
GermanyStudy of Atezolizumab and Drug Combination for Patients with Relapsed or Refractory Hodgkin's Lymphoma Eligible for Stem Cell Transplant
ItalyStudy on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment
CzechiaStudy on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
